Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01407107 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01407107 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT01407107, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether topical nitroglycerin in addition to 5-flourouracil and radiation therapy are effective in the treatment of operable rectal cancer.
Interventions
- DRUG Nitroglycerin 0.2 MG/HR
- DRUG Nitroglycerin 0.4 MG/HR
- DRUG Nitroglycerin 0.6 MG/HR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01407107
The ClinicalTrials.gov registry entry for NCT01407107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nitroglycerin 0.2 MG/HR is the first listed.
NCT01407107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01407107 about?
NCT01407107 is a clinical study titled "Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer". The purpose of this study is to determine whether topical nitroglycerin in addition to 5-flourouracil and radiation therapy are effective in the treatment of operable rectal cancer.
What is the current status of trial NCT01407107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01407107?
The interventions under investigation include: Nitroglycerin 0.2 MG/HR (DRUG), Nitroglycerin 0.4 MG/HR (DRUG), Nitroglycerin 0.6 MG/HR (DRUG).
Who is sponsoring clinical trial NCT01407107?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.